Your browser doesn't support javascript.
loading
Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population.
Zhou, Liqun; Yang, Kaiwei; Li, Xuesong; Ding, Yi; Mu, Dawei; Li, Hanzhong; Yan, Yong; Li, Jinyi; Wang, Dongwen; Li, Wei; Cong, Yulong; Gao, Jiangping; Ma, Kewei; Xiao, Yajun; Zhang, Sheng; Jiang, Hongyi; Hu, Weilie; Wei, Qiang; Jin, Xunbo; Guan, Zhichen; Liu, Qingyong; Xu, Danfeng; Gao, Xin; Jiang, Yongguang; Gan, Weimin; Sun, Guang; Wang, Qing; Liu, Yanhui; Hou, Jianquan; Xie, Liping; Song, Xishuang; Jin, Fengshuo; Feng, Jiafu; Cai, Ming; Liang, Zhaozhao; Zhang, Jie; Ye, Dingwei; Qi, Lin; Ma, Lulin; Shou, Jianzhong; Dai, Yuping; Shao, Jianyong; Tian, Ye; Hong, Shizhe; Xu, Tao; Kong, Chuize; Kang, Zefeng; Liu, Yuexin; Qu, Xun; Shi, Benkang.
Afiliación
  • Zhou L; Department of Urology, Peking University First Hospital, Beijing, China.
  • Yang K; Institute of Urology, Peking University, Beijing, China.
  • Li X; National Urological Cancer Center, Beijing, China.
  • Ding Y; Department of Urology, Peking University First Hospital, Beijing, China.
  • Mu D; Institute of Urology, Peking University, Beijing, China.
  • Li H; National Urological Cancer Center, Beijing, China.
  • Yan Y; Department of Urology, Peking University First Hospital, Beijing, China.
  • Li J; Institute of Urology, Peking University, Beijing, China.
  • Wang D; National Urological Cancer Center, Beijing, China.
  • Li W; Department of Urology, Peking University First Hospital, Beijing, China.
  • Cong Y; Institute of Urology, Peking University, Beijing, China.
  • Gao J; National Urological Cancer Center, Beijing, China.
  • Ma K; Air Force General Hospital, PLA, Beijing, China.
  • Xiao Y; Department of Urology, Peking Union Medical College Hospital, Beijing, China.
  • Zhang S; Department of Urology, Beijing Chao-Yang Hospital, Beijing, China.
  • Jiang H; Department of Urology, Armed-Police General Hospital, Beijing, China.
  • Hu W; Department of Urology, Shanxi Medical University First Hospital, Taiyuan, China.
  • Wei Q; Department of Urology, Hebei Medical University Second Hospital, Shijiazhuang, China.
  • Jin X; Department of Urology, The General Hospital of the People's Liberation Army, Beijing, China.
  • Guan Z; Department of Urology, The General Hospital of the People's Liberation Army, Beijing, China.
  • Liu Q; Department of Urology, First Affiliated Hospital of Jilin University, Changchun, China.
  • Xu D; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Gao X; Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Jiang Y; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
  • Gan W; Department of Urology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China.
  • Sun G; Department of Urology, West China School of Medicine, Chengdu, China.
  • Wang Q; Department of Urology, Shangdong Province-owned Hospital, Jinan, China.
  • Liu Y; Department of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Hou J; Department of Urology, The Central Hospital of Jinan City, Jinan, China.
  • Xie L; Department of Urology, Shanghai Changzheng Hospital, Shanghai, China.
  • Song X; Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Jin F; Department of Urology, Beijing Anzhen Hospital of Capital Medical University, Beijing, China.
  • Feng J; Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Cai M; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Liang Z; Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Wulumuqi, China.
  • Zhang J; Department of Urology, Guangdong General Hospital, Guangzhou, China.
  • Ye D; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Qi L; Department of Urology, The First Hospital of Zhejiang Province, Hangzhou, China.
  • Ma L; Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Shou J; Department of Urology, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, China.
  • Dai Y; Department of Urology, Mianyang Central Hospital, Mianyang, China.
  • Shao J; Department of Urology, General Hospital of PLA General Staff Headquarters, Beijing, China.
  • Tian Y; Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Hong S; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China.
  • Xu T; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Kong C; Department of Urology, Xiangya Hospital of Central South University, Changsha, China.
  • Kang Z; Department of Urology, Peking University Third Hospital, Beijing, China.
  • Liu Y; Department of Urology, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China.
  • Qu X; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Shi B; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Asian J Urol ; 6(1): 114-121, 2019 Jan.
Article en En | MEDLINE | ID: mdl-30775255
ABSTRACT

OBJECTIVE:

To evaluate the diagnostic value of fluorescence in situ hybridization (FISH) in bladder cancer.

METHODS:

We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) values were calculated for both the FISH and urine cytology tests.

RESULTS:

A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population. A total of 4807 patients with hematuria were prospectively, randomly enrolled for the simultaneous analysis of urine cytology, FISH testing, and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen. Overall, the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%, while that of cytology was 33.4% (p < 0.001). The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7% and 89.6%, respectively (p = 0.004). The sensitivity values of FISH for low and high grade bladder cancer were 82.6% and 90.1%, respectively (p = 0.002).

CONCLUSION:

FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages. Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Idioma: En Revista: Asian J Urol Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Idioma: En Revista: Asian J Urol Año: 2019 Tipo del documento: Article País de afiliación: China